These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2250300)

  • 1. Schedule dependence for cisplatin and etoposide multifraction treatments of spheroids.
    Durand RE; Vanderbyl SL
    J Natl Cancer Inst; 1990 Dec; 82(23):1841-5. PubMed ID: 2250300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of etoposide and cisplatin in an in vitro tumor model.
    Durand RE; Goldie JH
    Cancer Treat Rep; 1987; 71(7-8):673-9. PubMed ID: 3607781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicell spheroids as a model for cell kinetic studies.
    Durand RE
    Cell Tissue Kinet; 1990 May; 23(3):141-59. PubMed ID: 2192799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor resistance to therapy: a genetic or kinetic problem?
    Durand RE; Vanderbyl SL
    Cancer Commun; 1989; 1(5):277-83. PubMed ID: 2702035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
    Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
    Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell fusion studies to examine the mechanism for etoposide resistance in Chinese hamster V79 spheroids.
    Luo C; Johnston PJ; MacPhail SH; Banáth JP; Oloumi A; Olive PL
    Exp Cell Res; 1998 Sep; 243(2):282-9. PubMed ID: 9743588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer.
    Planting A; Kho S; van der Burg M; Goey H; Schellens J; van den Bent M; van der Gaast A; de Boer-Dennert M; Stoter G; Verweij J
    Cancer Chemother Pharmacol; 1997; 40(4):347-52. PubMed ID: 9225954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
    Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.
    Ignatiadis M; Mavroudis D; Veslemes M; Boukovinas J; Syrigos K; Agelidou M; Agelidou A; Gerogianni A; Pavlakou G; Tselepatiotis E; Nikolakopoulos J; Georgoulias V
    Clin Lung Cancer; 2005 Nov; 7(3):183-9. PubMed ID: 16354313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot study of ambulatory infusional delivery of a multidrug regimen: cisplatin, 5-fluorouracil and leucovorin (PFL) +/- etoposide.
    Lokich J; Anderson N; Moore C; Bern M; Coco F; Dow E; Zipoli T; Gonzalves L
    J Infus Chemother; 1996; 6(1):43-6. PubMed ID: 8748007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin and CCNU synergism in spheroid cell subpopulations.
    Durand RE
    Br J Cancer; 1990 Dec; 62(6):947-53. PubMed ID: 2257225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemosensitivity testing in V79 spheroids: drug delivery and cellular microenvironment.
    Durand RE
    J Natl Cancer Inst; 1986 Jul; 77(1):247-52. PubMed ID: 2425117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergism of cisplatin and mitomycin C in sensitive and resistant cell subpopulations of a tumor model.
    Durand RE
    Int J Cancer; 1989 Nov; 44(5):911-7. PubMed ID: 2511158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repair during multifraction exposures: spheroids versus monolayers.
    Durand RE
    Br J Cancer Suppl; 1984; 6():203-6. PubMed ID: 6582906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer.
    Johnson FM; Kurie JM; Peeples BO; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
    Oncology (Williston Park); 2003 Jul; 17(7 Suppl 7):17-21. PubMed ID: 12886869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
    Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S
    Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.
    Williams SD; Birch R; Einhorn LH; Irwin L; Greco FA; Loehrer PJ
    N Engl J Med; 1987 Jun; 316(23):1435-40. PubMed ID: 2437455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of etoposide resistance by measuring DNA damage in individual Chinese hamster cells.
    Olive PL; Banáth JP; Durand RE
    J Natl Cancer Inst; 1990 May; 82(9):779-83. PubMed ID: 2325148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
    Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH
    Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.